‘End of the Road’ for Trabectedin in Ovarian Cancer?

March 21, 2019 7:00 pm

By Ian Ingram

Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations.

Trabectedin (Yondelis) plus pegylated liposomal doxorubicin (PLD) failed to improve survival in a phase III trial of third-line ovarian cancer, but a survival … Read more

Patients Need Access to More Information About the Cost of Cancer Care

March 21, 2019 5:00 pm

By Brielle Benyon

Financial distress puts a major burden on patients with cancer and their families. And while there are numerous resources that clinicians can share with their patients to help with co-pays and other money-related issues, they are not … Read more

Avelumab Combo Falls Short in Advanced Ovarian Cancer

March 20, 2019 7:00 pm

By Ian Ingram

But showed promise in PD-L1-positive group.

Adding avelumab (Bavencio) to pegylated liposomal doxorubicin (PLD) failed to improve survival outcomes for patients with platinum-resistant or refractory ovarian cancer in a phase III trial reported here.

In the intent-to-treat … Read more

Early Data Send Strong Signal in Advanced Gyn Cancers

March 19, 2019 7:00 pm

By Ian Ingram

Clinical benefit rate tops 90% in pair of single-center studies.

Two early trials of novel combinations showed promising clinical activity in gynecologic cancers at a late-breaking abstract session at the Society of Gynecologic Oncology (SGO) meeting here.… Read more

New Class of Drugs Could Treat Ovarian Cancer

March 19, 2019 5:00 pm

A team of researchers across The University of Manchester have shown that a new class of drugs are able to stop ovarian cancer cells growing.

The Cancer Research UK and Wellcome Trust funded study, published in the journal Cancer CellRead more

SGO 2019: Pembrolizumab Combo Shows Clinical Benefit for Recurrent Epithelial Ovarian Cancer

March 19, 2019 3:00 pm

By Christina Bennett, MS

Pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide showed clinical activity in patients with recurrent epithelial ovarian cancer, according to the results of an open-label phase II trial (LBA4) presented at the 2019 Society of … Read more

Individualized Dosing Regimen Reduces Side Effects in Ovarian Cancer Maintenance Therapy

March 18, 2019 7:00 pm

By Kristie L. Kahl

Side effects decreased among patients with high-risk ovarian cancer who received an individualized starting dose of Zejula (niraparib), based upon baseline bodyweight and platelet counts, compared with a fixed starting dose, according to a recent analysis

Read more

When PARP Inhibitors Fail in Ovarian Cancer

March 18, 2019 6:00 pm

By Ian Ingram

Study identifies subgroup for whom another go could be worthwhile.

Lack of response to a PARP inhibitor in epithelial ovarian cancer didn’t necessarily mean patients were resistant to all such agents, a small retrospective study indicated.

Among … Read more

Lenvatinib Combo Yields Favorable Responses in Ovarian, Endometrial Cancers

March 18, 2019 3:30 pm

By Kristie L. Kahl

Lenvatinib (Lenvima) in combination with weekly paclitaxel induced activity among those with recurrent endometrial and platinum-resistant epithelial ovarian cancer, resulting in a 65% overall response rate (ORR), according to results from a phase I study presented … Read more

PARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Cancer

March 17, 2019 6:00 pm

By Ian Ingram

In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients’ time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.

Compared with placebo, … Read more

SGO 2019: Dendritic Cell-Based Immunotherapy Appears Promising for Recurrent Ovarian Cancer

March 16, 2019 5:00 pm

The treatment offers long-lasting anti-tumor immunity.

The addition of a dendritic cell immunotherapy to chemotherapy has been found to prolong overall survival significantly in patients with recurrent ovarian cancer. The combination of chemotherapy + immunotherapy corresponded to 73% survival after … Read more

Targeting Stem-Like Cells Could Prevent Ovarian Cancer Recurrence

March 12, 2019 5:00 pm

Ovarian cancer is not the most common form of cancer, but it’s among the deadliest. That’s because about 70 percent of cases recur. A new study by researchers at the University of Pittsburgh, UPMC Hillman Cancer Center, Magee-Women’s Research Institute … Read more

Lymphadenectomy Found Not Beneficial in Advanced Ovarian Cancer

March 7, 2019 3:00 pm

By Susan Moench

The results from the Lymphadenectomy in Ovarian Neoplasms (LION) trial, published in the New England Journal of Medicine, which compared systematic pelvic and paraaortic lymphadenectomy with no lymphadenectomy in some women with advanced ovarian cancer, showed … Read more

Anti-CD47 Antibody Trial in Advanced Cancers Shows Treatment Appears Safe, Well-Tolerated

March 6, 2019 5:00 pm

By Krista Conger

Over the years, I’ve written quite a bit about a protein called CD47 that is found on the surface of many types of cancer cells, as well as on aging red blood cells.

In 2009, researchers in … Read more

AI Predicts Ovarian Cancer Survival Rates From CT Scans

February 15, 2019 5:00 pm

By Melissa Rohman

AI can predict a woman’s survival rate and response to treatments for ovarian cancer more accurately than current methods, according to research published online Feb. 15 in Nature Communications. 

The machine learning software developed by researchers at … Read more

The First-Ever Clinical Trial Using Tocotrienols with Ovarian Cancer Patients, Increased their Survival by Seventy Percent in Refractory Ovarian Cancer

February 7, 2019 3:00 pm

A recent study conducted at Denmark’s Vejle Hospital, published in Pharmacological Research, provides evidence of delta-tocotrienol’s benefits for cancer patients. Results of the open-label trial suggest that American River Nutrition-manufactured delta-tocotrienol in combination with bevacizumab had additive effects in chemotherapy … Read more

Drug Treating Breast Cancer May Be Effective in Treating Lung and Ovarian Cancer

February 5, 2019 4:00 pm

Two new papers, published simultaneously in Nature Communications and led by researchers at McGill University, offer promise that a drug currently used to treat estrogen positive breast cancer may be effective in treating two different types of cancer, one rare … Read more

Survival Benefit With GI-Based Adjuvant Chemotherapy Regimen in Mucinous Ovarian Cancer

February 4, 2019 8:00 pm

By Kristi Rosa

Data from a retrospective study suggests an adjuvant gastrointestinal (GI)-based chemotherapy regimen is more beneficial than one that is gynecologic-based in patients with mucinous ovarian cancer, said Katherine C. Kurnit, MD.

“Right now, mucinous ovarian cancer is … Read more

Drug Target Identified for Chemotherapy-Resistant Ovarian, Breast Cancer

February 4, 2019 5:00 pm

By Tamara Bhandari

Study finds mimic for BRCA genes that could be targeted to improve treatment

People who inherit a faulty copy of the so-called “breast cancer genes” BRCA1 and BRCA2 are at high risk of cancer. About 10 percent … Read more

Alisertib-Based Combo Improves Survival Outcomes in Ovarian, Breast Cancer

January 21, 2019 10:30 am

By Jessica Skarzynski

For some time now, paclitaxel has been considered standard of care in the treatment of patients with platinum-resistant ovarian cancer; however, recent research has shown the addition of the investigational drug alisertib to a paclitaxel regimen demonstrated … Read more